{"id":"topical-pimecrolimus-treatment","safety":{"commonSideEffects":[{"rate":"10–25","effect":"Application site burning or irritation"},{"rate":"5–15","effect":"Pruritus at application site"},{"rate":"5–10","effect":"Skin infections (secondary bacterial or viral)"},{"rate":"2–5","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pimecrolimus binds to calcineurin and prevents its interaction with NFAT (nuclear factor of activated T cells), thereby blocking T-cell proliferation and the release of pro-inflammatory mediators. When applied topically, it reduces skin inflammation without the systemic immunosuppression associated with oral calcineurin inhibitors, making it suitable for localized inflammatory skin conditions.","oneSentence":"Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:22.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis (eczema)"},{"name":"Allergic contact dermatitis"},{"name":"Seborrheic dermatitis"}]},"trialDetails":[{"nctId":"NCT06241118","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-02-29","conditions":"Dermatitis Atopic","enrollment":390},{"nctId":"NCT07240389","phase":"NA","title":"Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.","status":"NOT_YET_RECRUITING","sponsor":"Milosz Pietrus","startDate":"2025-12-01","conditions":"Vulvar Lichen Sclerosus","enrollment":45},{"nctId":"NCT01082393","phase":"PHASE4","title":"Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-02-16","conditions":"Vitiligo","enrollment":14},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT02896101","phase":"PHASE3","title":"Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2016-08","conditions":"Atopic Dermatitis","enrollment":755},{"nctId":"NCT03834935","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba","status":"UNKNOWN","sponsor":"St Joseph University, Beirut, Lebanon","startDate":"2019-03-01","conditions":"Pityriasis Alba","enrollment":40},{"nctId":"NCT01692626","phase":"PHASE2","title":"1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2012-02","conditions":"Rash","enrollment":13},{"nctId":"NCT02443311","phase":"PHASE4","title":"Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2010-09","conditions":"Oral Lichen Planus","enrollment":24},{"nctId":"NCT00666159","phase":"PHASE4","title":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Dermatitis, Atopic","enrollment":226},{"nctId":"NCT00666302","phase":"PHASE4","title":"A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-10","conditions":"Dermatitis, Atopic","enrollment":413},{"nctId":"NCT00393263","phase":"PHASE2","title":"Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Center for Vulvovaginal Disorders","startDate":"2006-10","conditions":"Lichen Sclerosus","enrollment":38},{"nctId":"NCT00297037","phase":"PHASE2","title":"Pimecrolimus Cream for Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-08","conditions":"Oral Lichen Planus","enrollment":21},{"nctId":"NCT01524744","phase":"PHASE2","title":"A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","startDate":"2009-03","conditions":"Oral Lichen Planus","enrollment":40},{"nctId":"NCT01202149","phase":"PHASE4","title":"Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Frankel, Amylynne, M.D.","startDate":"2010-03","conditions":"Eczema, Atopic Dermatitis","enrollment":30},{"nctId":"NCT01177566","phase":"PHASE4","title":"Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.","status":"COMPLETED","sponsor":"Emer, Jason, M.D.","startDate":"2009-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00460083","phase":"PHASE4","title":"Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Ceragenix Pharmaceuticals","startDate":"2007-04","conditions":"Atopic Dermatitis","enrollment":35},{"nctId":"NCT00121381","phase":"PHASE4","title":"Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"Dermatitis, Atopic","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"topical pimecrolimus treatment","genericName":"topical pimecrolimus treatment","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin. Used for Atopic dermatitis (eczema), Allergic contact dermatitis, Seborrheic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}